Abstract
Ventricular assist devices are increasingly being used for mechanical support in patients with advanced heart failure. However, thromboembolism remains a leading cause of mortality in this population. We describe the successful treatment of native aortic valve thrombosis with bivalirudin in a patient with factor V Leiden mutation, who had undergone left ventricular assist device implantation, preventing the need for further surgical intervention.
MeSH terms
-
Antithrombins / therapeutic use*
-
Aortic Valve
-
Bicuspid Aortic Valve Disease
-
Coronary Thrombosis / drug therapy*
-
Coronary Thrombosis / etiology
-
Female
-
Heart Defects, Congenital / drug therapy*
-
Heart Defects, Congenital / etiology
-
Heart Valve Diseases / drug therapy*
-
Heart Valve Diseases / etiology
-
Heart-Assist Devices / adverse effects*
-
Hirudins
-
Humans
-
Middle Aged
-
Peptide Fragments / therapeutic use*
-
Recombinant Proteins / therapeutic use
Substances
-
Antithrombins
-
Hirudins
-
Peptide Fragments
-
Recombinant Proteins
-
bivalirudin